Sharemaestro Newsreel

Adaptive Biotechnologies CCO Susan Bobulsky sells $75,000 in shares By Investing.com

Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 3,000 shares of common stock totaling $75,000 at $25.00 per share on August 10, 2026. This transaction was executed under a Rule 10b5-1 trading plan and occurred while the stock was trading near its 52-week high …

Quest Diagnostics Keeps Quarterly Dividend at $0.86 per Share, Payable Oct. 21, to Shareholders of Record Oct. 6

Quest Diagnostics (DGX) announced that it will maintain its quarterly dividend at $0.86 per share. This dividend will be payable on October 21, 2026, to shareholders of record as of October 6, 2026. The announcement was published on August 12, 2026, by MT Newswires.

Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells $14,182,880.88 in Stock

Twist Bioscience CEO Emily Leproust sold 113,318 shares of company stock for over $14.18 million, reducing her ownership by 12.16%. This sale was executed under a pre-arranged Rule 10b5-1 trading plan, with the stock trading near its one-year high. Despite missing EPS estimates, analysts …

ICON PLC (ICLR) director Linda Grais sells shares to cover taxes, gets new RSU grant

ICON PLC director Linda Grais reported equity transactions including the vesting of 1,732 restricted share units (RSUs) and a new grant of 1,324 RSUs. To cover tax withholding obligations, Grais sold 841 ordinary shares in non-discretionary "sell to cover" transactions at weighted average prices …

ICON plc (ICLR) director’s RSU vesting triggers tax-related share sales

ICON plc director Julie O'Neill reported equity award activity, including the vesting of 1,732 restricted share units (RSUs) on August 10, 2026, and the grant of 1,324 new RSUs. To cover tax withholding obligations associated with the vesting, O'Neill sold 915 ordinary shares in …

ICON PLC (ICLR) awards 1,324 Restricted Share Units to director Kevin Francis Egan

ICON PLC (ICLR) director Kevin Francis Egan was granted 1,324 Restricted Share Units (RSUs) on August 10, 2026. These RSUs represent a contingent right to receive one ordinary share each upon vesting, which is scheduled for May 22, 2027. A nominal conversion price of …

ICON PLC (ICLR) director reports RSU vesting, new grant and tax sell-to-cover sales

ICON PLC director Eugene Pacelli McCague reported a series of equity transactions, including the vesting of 1,732 restricted share units (RSUs) on August 10, 2026, and a new grant of 1,324 RSUs on the same day. He also sold 841 ordinary shares on August …

ICON PLC (ICLR) awards 5,886 restricted share units to Chief Accounting Officer

ICON PLC (ICLR) has awarded Chief Accounting Officer Emer Lyons 5,886 Restricted Share Units (RSUs). These RSUs, granted on August 10, 2026, will vest in three equal installments on May 22, 2027, May 22, 2028, and May 22, 2029. Each RSU represents a contingent …

Does CareDx’s Profit Jump And Higher 2026 Outlook Change The Bull Case For CDNA?

CareDx (CDNA) reported strong Q2 2026 results with significant profit and raised its full-year 2026 revenue guidance to US$490–500 million, while also completing a share buyback and filing for an ESOP-related share registration. Despite this positive financial performance and a Medicare LCD confirming coverage …

Sotera Health Company’s Q2 Earnings Call: Our Top 5 Analyst Questions

Sotera Health reported strong Q2 2026 results with broad-based growth across its business units, exceeding analyst estimates for revenue, EPS, and EBITDA, and subsequently raising its full-year guidance. The article highlights five key analyst questions from the earnings call, focusing on drivers of Nelson …

Revvity Inc. stock outperforms competitors on strong trading day

Revvity Inc. (RVTY) stock advanced 1.86% to $117.88 on Wednesday, outperforming the S&P 500 Index and the Dow Jones Industrial Average. The stock closed just 0.35% shy of its 52-week high of $118.30. This performance occurred on a mixed trading day for the broader …

Twist Bioscience CEO Emily Leproust Executes Stock Option Exercise and Sells 113,318 Shares Under 10b5-1 Plan

Emily M. Leproust, CEO of Twist Bioscience Corp (NASDAQ:TWST), exercised stock options for 113,318 shares and subsequently sold them for a weighted average price of $125.1615 per share on August 10, 2026. These transactions were executed under a Rule 10b5-1 trading plan established in …

Medpace Holdings (MEDP) CEO sells 23,144 shares, reports 4.73M held via LLC

Medpace Holdings, Inc. President & CEO August J. Troendle sold a total of 23,144 shares of Medpace common stock on August 10 and 11, 2026, for approximately $13.98 million. The sales were executed through limit orders during an open window period. Troendle also reported …

Twist Bioscience (TWST) insider Leproust plans resale after option exercise

Twist Bioscience insider Emily M. Leproust has filed to resell up to 19,952 shares of common stock, valued at over $2.49 million, following a stock option exercise on August 12, 2026. This transaction is detailed in a Form 144 SEC filing, which also indicates …

Quest Diagnostics Declares Quarterly Cash Dividend

SECAUCUS, N.J., Aug. 12, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest …

Quest Diagnostics Sets Oct. 21 Date for Cash Dividend

Quest Diagnostics (NYSE: DGX) has announced a quarterly cash dividend of $0.86 per share. The dividend will be payable on October 21, 2026, to shareholders of record as of October 6, 2026. This move reflects the company's commitment to providing direct cash returns to …

Guardant Health, Inc. SEC Filing (Aug 12, 2026)

Guardant Health, Inc. filed a Form 144 with the SEC on August 12, 2026, detailing a proposed sale of 46,300 common shares acquired through employee stock option exercise. The aggregate market value of these securities to be sold is $7,645,219.00, with Charles Schwab & …

CareDx (CDNA) insider Peter Maag files to sell 7,000 NASDAQ-listed shares

CareDx, Inc. insider Peter Maag has filed a notice to sell 7,000 shares of common stock, valued at $328,237.70, through Morgan Stanley Smith Barney LLC. These shares originated from restricted stock awards in late 2023 and early 2024. The filing also disclosed recent sales …

Labcorp president & CEO Adam Schechter sells $1.5m in company stock

Adam H. Schechter, President & CEO of Labcorp Holdings Inc., sold 4,669 shares of company stock for approximately $1.5 million. The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan. This transaction occurred as LH stock traded near its 52-week high, following …

Insider Selling: Labcorp (NYSE:LH) CEO Sells 4,669 Shares of Stock

Labcorp CEO Adam Schechter sold 4,669 shares of company stock for approximately $1.50 million under a pre-arranged trading plan, reducing his total ownership by 4.35%. This sale occurred while Labcorp shares traded near their 52-week high, following strong quarterly earnings that surpassed analyst expectations. …

Amgen Stock And The Price Of A Promise

Amgen recently raised its full-year revenue guidance, typically a positive signal, but its stock has not seen a significant celebratory pop. While the company's current performance is strong with multiple products showing double-digit growth, the market appears to have already factored this in. Investors …

NeoGenomics Senior VP & Chief Accounting Officer Gregory Aunan Sells 80% Of Holding

NeoGenomics' Senior VP & Chief Accounting Officer, Gregory Aunan, recently sold US$321k worth of shares, representing an 80% reduction in his holdings at an average price of US$16.07. This significant insider selling event, occurring slightly below the current share price of US$16.53, raises caution …

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3

Agilent Technologies Inc. announced that the FDA has approved the expanded use of its PD-L1 IHC 22C3 pharmDx for Dako Omnis platform. This approval allows for identifying patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma …

Thermo Fisher, Michael J. Fox Foundation Expand Parkinson’s Proteomics Resource with 5,500 Samples

Thermo Fisher Scientific and The Michael J. Fox Foundation have expanded the Parkinson’s Precision Medicine Initiative (PPMI) proteomic data resource by analyzing approximately 5,500 research samples using Olink Explore HT technology. This large-scale, open-access dataset is now available in PPMI’s repository to the global …

Onconetix (NASDAQ: ONCO) resale filing covers 100M shares tied to PIPE

Onconetix (NASDAQ: ONCO) has filed a Form S-1 registration statement for the resale of up to 100 million shares of common stock by selling stockholders, linked to a July 2026 PIPE financing. These shares are convertible from Series F preferred stock, with an initial …

A Look at Veracyte Inc (VCYT) After 3.7% Decline -- GF Value $38

Veracyte Inc (VCYT) shares recently declined by 3.7%, trading at $44.68, which is 15.6% above its GF Value™ estimate of $38.64, indicating it is "modestly overvalued." Despite a strong GF Score™ of 82/100, driven by high growth and financial strength, the company has a …

Agilent Technologies, Inc. Stock 12‑Month Price Target Raised to $160.17, Implies 7% Upside

The average 12-month price target for Agilent Technologies, Inc. (A) stock has been raised from $159.33 to $160.17 by 18 analysts, with forecasts ranging from $135 to $185 per share. This new target implies a potential upside of approximately 7% from the August 11 …

Is Labcorp Holdings (LH) Fully Priced Following Oncology Approvals And Raised Outlook?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced …

Thermo Fisher Beat Estimates by $300 Million in Q2. Is the Recovery Finally Here?

How Investors May Respond To Veracyte (VCYT) Raising 2026 Revenue Guidance After Returning To Profit

BMRN vs. ILMN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. …

Illumina Inc (ILMN) News, Articles, Events & Latest Updates

Guardant Health, Inc. (GH) Stock Price, News, Quote & History

Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?

Tempus AI, Inc. TEM is showing faster oncology testing growth, rising data demand and improving adjusted profitability. Management also raised its 2026 revenue outlook after second-quarter results topped expectations. The counterweight is valuation. TEM still trades at a premium to the broader medical sector, …

Charles River Laboratories stock hits 52-week high at $285.13 By Investing.com

Charles River Laboratories International Inc. (CRL) stock has reached a 52-week high of $285.13, reflecting an 83.28% increase over the past year and a 41.4% year-to-date return. This surge follows strong second-quarter earnings that surpassed analyst expectations and led to increased price targets from …

Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Todd Spencer Chief Executive Officer - Birgit Girshick Executive Vice President and Chief Financial Officer - Glenn Coleman Full Conference Call Transcript …